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Although human papillomaviruses (HPV) and adenoviruses (Ad) both transform cells by expressing functionally related
oncogenes (Ad-E1A/E1B; HPV-E7/E6), only HPV are oncogenic in humans. Prior studies have shown that HPV-transformed
cells are resistant to NK cell lysis and E7- and E6-specific CTL are inefficiently generated in women with HPV-induced
cervical cancer. Therefore, we postulated that the dissimilar oncogenicities of Ad and HPV may be caused by a protective
NK and T cell response that is triggered by transformed cells expressing E1A, but not by E7. To test this hypothesis, mice
that were either immunologically intact, lacked T cells, or lacked both NK and T cells were challenged with Ad serotype 5
(Ad5)-E1A- or HPV16-E7-transfected tumor cells. E7-expressing tumor cells were resistant to NK cell lysis in vitro and failed
to elicit a measurable anti-tumor NK or T cell response in vivo. The concomitant expression of E6 did not change this
phenotype. In contrast, E1A-expressing tumor cells were sensitive to NK lysis in vitro and triggered a protective NK and T
cell immune response in vivo. These data suggest differences in the capacities of E1A or E7 oncoproteins to trigger
protective anti-tumor immune responses may contribute to the dissimilar oncogenicities of Ad and HPV in humans. © 2000
Academic Press
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SINTRODUCTION
Human papillomaviruses (HPV)2 and adenoviruses
(Ad) are common human pathogens with a proclivity for
causing persistent infections. In the United States, 95% of
adults are seropositive for one of the group C Ad, and
over 12 million adults are infected with genital tract HPV
(Koutsky et al., 1988; Straus, 1984). Although both viruses
are competent to transform human cells, only HPV are
oncogenic in humans (Bosch et al., 1995; Green et al.,
1979).
In HPV-induced human malignancies or Ad-trans-
formed cells, there is viral gene integration into the host
genome, and expression of two viral genes (HPV, E6 and
E7; Ad, E1A and E1B) is found consistently (Graham et
al., 1977; Schwarz et al., 1985; Smotkin and Wettstein,
986). E1A and E7 are the primary immortalizing genes of
d and HPV, respectively. Ad-E1B and HPV-E6 serve as
helper” genes that increase the efficiencies of E1A- and
7-induced transformation (Halbert et al., 1991; Houwel-
1 To whom correspondence and reprint requests should be ad-
dressed at the National Medical and Research Center, Dept. of Med-
icine, 1400 Jackson St., Denver, CO 80206. Fax: 303-398-1806. E-mail:
routesj@njc.org.c
r
2 Abbreviations used: Adenovirus, Ad; adenovirus serotype 5, Ad5;
human papillomavirus, HPV.
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48ng et al., 1980). The E1A and E7 oncoproteins appear to
ransform cells by similar molecular mechanisms.
hrough two highly homologous, conserved regions
conserved region (CR) 1 and CR2], the E1A and E7
ncoproteins bind to and inhibit the function of common
ell-growth regulatory proteins (e.g., p105 or retinoblas-
oma gene product, pRb; p107, p130, and cyclin A) (Dyson
t al., 1992; Phelps et al., 1988; Vousden and Jat, 1989).
lthough genetically unrelated, Ad-E1B p55 and E6 on-
oproteins derived from oncogenic HPV both inhibit the
iological activities of the tumor suppressor gene p53
hrough different molecular mechanisms (Scheffner et
l., 1990; Yew and Berk, 1992; Zantema et al., 1985). As a
esult of this activity, both E1B and E6 inhibit either E1A-
r E7-induced cellular apoptosis and favor the survival of
mmortalized cells (Pan and Griep, 1994; Rao et al., 1992).
HPV are frequently divided into two major classes
ased on their associations with cervical cancer. The
low-risk” types (HPV-6, HPV-11) cause benign cervical
esions. In contrast, “high-risk” HPV (HPV-16, -18, -31 and
33) are identified in over 95% of cervical carcinomas.
he dissimilar oncogenicities of high- and low-risk HPV
ikely relate to the inability of low-risk HPV to transform
uman cells (Heck et al., 1992; Mu¨nger et al., 1991;
cheffner et al., 1990). Unlike low-risk HPV, Ad are fully
ompetent to transform human cells. This fact and the
esults of previous studies comparing other DNA tumor
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49DISSIMILAR IMMUNOGENICITIES OF E7- AND E1A-EXPRESSING CELLSviruses indicate that there are factors other than cellular
transformation efficiency that distinguish tumorigenic
from nontumorigenic viruses. For example, although non-
oncogenic group C Ad (Ad serotype 2, Ad2, Ad5) and
highly oncogenic group A Ad (Ad 12) transform rodent
cells in vitro with similar efficiencies, only cells trans-
ormed by highly oncogenic serotypes form tumors in
mmunocompetent animals. Conversely, cells trans-
ormed in vitro by both types of viruses are tumorigenic in
immunodeficient animals (Lewis and Cook, 1984). These
and other data suggest that the outcomes of interactions
between oncogene-expressing, virally transformed cells
and the host cellular immune response are pivotal in
determining whether primary tumors will or will not form
in vivo.
In previous studies we showed that the oncogenicities
of HPV- or Ad-transformed human cells correlated with
their resistance to lysis by human NK cells (Routes and
Ryan, 1995). Oncogenic, HPV transformed human cells
were resistant to NK lysis, whereas Ad-transformed hu-
man cells were NK sensitive. The Ad-E1A and HPV-E7
oncoproteins regulated this difference in susceptibility to
NK cell lysis. Additionally, several laboratories have re-
ported that HPV-tumor-specific CTL responses are weak
in women with cervical cancer (Borysiewicz et al., 1996;
Evans et al., 1996; Ressing et al., 1996). In contrast,
studies in rodents show that robust CTL responses are
induced following injection of Ad5-transformed cells
(Bellgrau et al., 1988). These data suggested to us that
differences in the capacities of E7 and E1A proteins to
target virally transformed cells for destruction by the
cellular immune response might contribute to the dissim-
ilar oncogenicities of HPV and Ad in humans. However,
there previously had been no way to directly compare the
immunogenicities of E1A- and E7-expressing tumor cells
to determine whether oncoprotein immunogenicity could
influence primary tumor development in vivo. Therefore,
it was uncertain whether these in vitro findings were
relevant to primary tumor development in vivo. (For these
considerations, tumor cell immunogenicity is defined as
the ability of the tumor cell to elicit an effective antitumor
response in vivo that includes both innate (NK cell) and
acquired (T cell) immune defenses).
To test the hypothesis that dissimilar NK and T cell
responses directed against cells expressing E1A or E7
affect primary tumor formation, a murine model was
developed using the C57/BL6-derived tumor cell line
MCA-102. MCA-102 cells were chosen for several rea-
sons. First, MCA-102 cells are highly oncogenic in im-
munocompetent animals. Second, MCA-102 cells are
nonimmunogenic, even when transduced by the co-
stimulatory molecules B7.1 or B7.2 (Chen et al., 1994;
Mule et al., 1987; Yang et al., 1995). Therefore, by trans-
fecting the E1A and E7 oncogenes into MCA-102 cells,
the immunogenicities of the E1A and E7 proteins could
be directly compared and the relevance of oncoprotein
w
Mimmunogenicity on primary tumor formation could be
assessed. Thus, if E1A were more immunogenic than E7,
then immunocompetent mice should more efficiently re-
ject MCA-102-E1A cells than MCA-102-E7 cells. Further-
more, if NK and T cells were important in the preferential
rejection of E1A-expressing cells, the NK cell-related and
T-cell-related components to the tumor rejection re-
sponse could be quantitated through the use of mice that
lack T cells (nude mice) or T cells and NK cells (CD3-e-
ransgenic mice). Finally, because nontransfected MCA-
02 cells were inherently resistant to killing by NK cells,
t was also possible to test the effect of E1A and E7
ncogene expression on NK cell susceptibility in vitro
nd to correlate these results with in vivo tumor devel-
pment data.
These results showed that the E1A- or E7-expressing
ouse tumor cells exhibited phenotypes similar to those
bserved for virally transformed human tumor cells. E7-
xpressing cells were resistant to rejection by animals
ith competent NK cell and T cell responses and were
esistant to NK cell lysis in vitro. Conversely, E1A-ex-
ressing cells were highly NK susceptible and over 1000
imes less tumorigenic in immunocompetent mice than
ither E7-expressing cells or nontransfected MCA-102
umor cells. The decreased tumorigenicity of E1A-ex-
ressing MCA-102 cells was dependent on an intact T
ell and NK cell antitumor immune response. These
tudies provide the first animal model in which the im-
unogenicities of these viral oncoproteins have been
irectly compared and shown to influence primary tumor
evelopment. The possible biological implications of
hese findings are discussed.
RESULTS
stablishment of MCA-102 transfectants expressing
igh levels of HPV-E7 or Ad-E1A oncoproteins
MCA-102 cells were transfected with either
LSXN16E7 or pE1A-neo. Geneticin-resistant colonies
ere screened for HPV-16-E7 or Ad5-E1A expression by
estern analysis. Levels of E7 oncoprotein expression in
CA-102-E7-CL1 and MCA-102-E7-CL2 were compared
o those in SiHa and H4-E7. SiHa is an HPV16-trans-
ormed human cervical cancer line that expresses low
evels of HPV16-E7, whereas H4-E7 is an HPV16-E7-
ransfected human fibrosarcoma cell line that expresses
igh levels of E7 (Routes and Ryan, 1995). As shown in
ig. 1, both MCA-102-E7-CL1 and MCA-102-E7-CL2 ex-
ressed considerably higher levels of the HPV16-E7 on-
oprotein than SiHa, but slightly lower levels than H4-E7.
imilarly, high levels of the Ad5-E1A oncoproteins were
xpressed in both MCA-102-E1A-CL1 and MCA-102-E1A-
L2 cells. The cell morphologies and in vitro doubling
imes of these E7- and E1A-expressing MCA-102 lines
ere indistinguishable from those of nontransfected,
CA-102 cells (data not shown).
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50 ROUTES ET AL.Failure of E7-expressing MCA-102 cells to elicit a
protective cellular immune response to primary
tumor development
The effects of E7 oncogene expression on primary
tumor development by MCA-102 cells was tested in mice
with varying abilities to mount an antineoplastic cellular
immune response (Fig. 2). If E7 expression were effective
in increasing the immunogenicity of MCA-102 cells, it
would be predicted that expression of this oncoprotein
would reduce tumorigenicity in immunocompetent mice
compared with that in T-cell-deficient, nude mice. This
was not the observation. Only a few thousand parental
MCA-102 cells were required to induce subcutaneous
tumors in immunocompetent mice (TPD50 mean 6
EM 5 3.3 6 0.4 cells) (Fig. 2 and Table 1). Expression
f high levels of E7 in two different transfected clones did
ot alter this level of tumorigenicity (TPD50 5 3.4 6 0.3
nd 2.8 6 0.2). This failure of E7 expression to alter
umorigenicity was also observed with cells co-express-
ng HPV E6 (TPD50 5 3.0 6 0.3). There was also no
ifferential effect of E7 expression on MCA-102 tumor
evelopment in T-cell-deficient nude mice (Fig. 3). Both
arental MCA-102 cells and E7-expressing cells were
lightly more tumorigenic in nude than in immunocom-
etent mice, as indicated by the slightly lower TPD50
values of each cell type in nude mice (Fig. 3 vs Fig. 2).
There were, however, no significant differences in the
tumor-inducing capacities of E7-expressing cells com-
pared with parental cells when compared in either nude
(Fig. 3) or normal mice (Fig. 2). These data suggested
that E7 expression does not induce an effective T-cell-
dependent defense against primary tumor formation by
MCA-102 cells.
MCA-102 cells are inherently nonimmunogenic in syn-
geneic C57/BL6 mice (Chen et al., 1994; Mule et al., 1987;
ang et al., 1995). Therefore, it was possible that these
ells possessed some trait that limited the immunogenic
ffects of any transfected viral oncoproteins. This possi-
ility was tested in two ways. MCA-102 cells expressing
1A, rather than E7, were tested in the same tumorige-
icity assays in immunocompetent mice (Fig. 2). In con-
FIG. 1. (A) Expression of HPV16-E7 oncoprotein MCA-102-E7-CL1,
MCA-102-E7-CL2, SiHa, and H4-E7 cell lines measured by Western
analysis. (B) Expression of Ad5-E1A protein in MCA-102-E1A-CL1 and
-CL2 cells measured by Western analysis.rast to E7 expression, E1A expression caused a three-
o four-log decrease in tumorigenicity of transfectedMCA-102 cells, as indicated by the respective increases
in the numbers of cells required to induce tumors in 50%
of animals (TPD50 of E1A-positive cells, E1A-CL1 5 6.8 6
0.4, E1A-C12 5 7.3 6 0.3 cells vs TPD50 of parental
ells 5 3.3 6 0.4 cells). This comparison of different
MCA-102 clones transfected with different viral onco-
genes could not exclude the possibility that clonal vari-
ation in the different transfectants contributed to the
differences in tumorigenicity. Therefore, in a second type
of experiment, an E7-transfected clone of MCA-102 cells
was supertransfected with E1A and retested for sensi-
FIG. 2. Tumor induction studies in normal, nude, and CD3-e-trans-
genic mice. Immunologically normal (A), nude (B), and CD3-e-trans-
genic mice (C) were injected subcutaneously in the flank with log
dilutions of MCA-102, MCA-102-E1A, and MCA-102-E7 cells and ob-
served weekly for 12 weeks. Animals were sacrificed when tumors
reached a mean diameter of 20 mm or at the end of a 12-week
observation period. The calculated TPD50 value represents the log10 of
the number of tumor cells required to produce tumors in 50% of the
mice.
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51DISSIMILAR IMMUNOGENICITIES OF E7- AND E1A-EXPRESSING CELLStivity to rejection by immunocompetent mice (Table 1).
These E7/E1A coexpressing cells exhibited the same
three-log reduction in tumorigenicity in immunocompe-
tent mice that was observed with cells expressing E1A
alone. This eliminated clonal selection as an explanation
for the observed differences in tumorigenic phenotypes
of the cells and further excluded the possibility that there
was some trait of E7-expressing cells that blocked ex-
pression of a rejection-susceptible phenotype. These
data suggested that, in contrast to E1A expression, E7
expression was weakly immunogenic (or nonimmuno-
genic) in MCA-102 cells and failed to elicit a protective
host defense against primary tumor formation.
E1A-expressing MCA-102 cells elicit both NK cell-
and T-cell-specific responses to primary tumor
challenge
The results of two types of animal experiments sug-
gested that, in addition to a T-cell-dependent rejection
response, the reduced tumorigenicity of E1A-expressing
MCA-102 cells was also dependent on NK cell-mediated
rejection. First, depletion of NK cells in vivo by pretreat-
ment of normal mice with the anti-NK antibody PK136
(Koo et al., 1986) increased the tumorigenicity of E1A-
xpressing cells, as evidenced by a 1.7-log reduction in
he number of MCA-102-E1A cells required to produce
umors (TPD50 in NK cell-depleted mice 5 4.8; TPD50 in
ntreated mice 5 6.5). Second, E1A-expressing MCA-
02 cells continued to be significantly less tumorigenic in
-cell-deficient nude mice than either parental MCA-102
r E7-expressing MCA-102 cells (TPD50 values, MCA-
02-E1A 5 4.5 vs MCA-102 5 1.8 and MCA-102-E7 5
.3). Nude mice have normal or increased NK cell activ-
ty. These results indicated that E1A but not E7 expres-
ion sensitized MCA-102 cells to an NK cell-dependent
ejection response that is discernible from CTL-depen-
TABLE 1
Tumor-Inducing Capacity, Class I MHC Antigen Surface Expression,
and NK Cell Killing of MCA-102 Lines
Cell line
TPD50
Normal mice
Class I MHC
antigen surface
expressiona (%)
Sensitivity
to NK cell
lysis
MCA-102 3.3 6 0.4 100 No
-E1A-CL1 6.8 6 0.4 120 6 5 Yes
-E1A-CL2 7.3 6 0.3 400 6 7 Yes
-E7-CL1 3.4 6 0.3 200 6 6 No
-E7-CL2 2.8 6 0.2 200 6 4 No
-E7/E6 3 6 0.3 220 6 3 No
-E1A/E7 6.7 6 0.2 290 6 5 Yes
a Surface class I MHC antigen levels were normalized to the levels
xpressed on MCA-102 cells.ent rejection.
It was also possible that T-cell-independent defensesther than NK cells contributed to the enhanced rejection
f E1A-, but not E7-, expressing cells in nude mice (Cook
t al., 1982). To test this, tumor induction studies were
one in CD3-e-transgenic mice, which lack both NK cells
nd T cells (Fig. 2C). There were no significant differ-
nces in the tumor-forming capacities of MCA-102-E1A
ells in these mice, compared with either parental MCA-
02 cells or MCA-102-E7 cells. Therefore, the incremen-
al deletion of the NK cell response in addition to the T
ell response that resulted from using CD3-e-transgenic
ice, rather than nude mice, resulted in complete elim-
nation of the host’s ability to reject E1A-expressing cells.
hese results also showed that the reduced tumorige-
icity of E1A-expressing MCA-102 cells in nude mice
as NK cell-dependent and was not explained by some
ther, lymphocyte-independent rejection mechanism.
nverse correlation between NK susceptibility of
ncogene-expressing tumor cells tested in vitro and
tumorigenicity in NK-competent animals
Next, we tested the susceptibilities of several MCA-
102 lines expressing either E7 or E1A to NK cell killing to
determine if patterns of lysis in vitro correlated with cell
line susceptibility to protective NK and T cell responses
in vivo (Fig. 3). Expression of E1A as a single oncogene
induced MCA-102 cells to become highly susceptible to
NK cell killing. In contrast, E7 expression resulted in no
increase in NK susceptibility compared with nontrans-
fected, MCA-102 cells. To exclude the possibility that
these NK susceptibility patterns were specific to the cell
clone, rather than the oncogene expressed, an E7-ex-
pressing clone of MCA-102 cells that had been super-
transfected with E1A and a second clone that had been
established by co-transfection with E7 and E6 were
tested in NK cell assays. E1A expression converted the
FIG. 3. Susceptibility of MCA-102 lines to NK cell lysis. NK lysis of
MCA-102-E1A-CL1, MCA-102-E7-CL1, MCA-102-E1A/E7, and MCA-102-
E7/E6 cells as measured by a 6-h. 51Cr-release cytolysis assay. Results
represent the means 6 SEM of four separate experiments. Equivalent
patterns and magnitude of NK cell killing were seen with MCA-102-
E1A-CL2 and MCA-102-E7-CL2 cells (data not shown).
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52 ROUTES ET AL.E7-expressing clone from an NK-resistant to an NK-
susceptible cell. This result indicated that E7 expression
did not select for an inherently NK-resistant clone. The
failure of the E7/E6 coexpressing MCA-102 clone to
exhibit NK susceptibility further indicated that the E7-
related resistant phenotype observed with the single
oncogene E7 transfectant was not a result of clonal
selection.
NK resistance and tumorigenicity of oncogene-
expressing MCA-102 cells do not correlate with the
level of class I MHC antigen expression
NK cells express inhibitory receptors that recognize
class I MHC antigens expressed on target cells (Lanier,
1998). In some experimental systems, cells that express
high levels of class I antigens are resistant to NK cell
killing, whereas cells that express low levels of class I
are NK sensitive (Lanier, 1998). If this were the explana-
tion for the oncogene-related NK and tumorigenic phe-
notypes observed in these studies, it would be predicted
that cells in which E1A expression had induced high-
level NK susceptibility would express very low levels of
class I MHC antigens, relative to NK-resistant parental
cells and E7-expressing cells. In contrast, it has also
been proposed that the escape of Ad- or HPV-trans-
formed cells from the T-cell-mediated cellular immune
response occurs as a result of downregulation of cell
surface expression of class I MHC antigens (Bernards et
al., 1983; Cromme et al., 1994; Schrier et al., 1983). If this
ere the case with the MCA-102 cells tested here, it
ould be predicted that the nonimmunogenic, E7-ex-
ressing MCA-102 cells tested here would express very
igh levels of class I antigen compared with the E1A-
xpressing cells. It was also possible that there was no
orrelation between class I MHC antigen expression and
usceptibility to NK killing or to T-cell-mediated rejection,
s had been reported from some studies of DNA virus-
ransformed rodent and human cells (Haddada et al.,
986, 1988; Routes and Cook, 1995).
To examine these relationships using the oncogene-
xpressing MCA-102 cells studied here, surface class I
HC antigen expression was measured by FACS anal-
sis (Table 1). The results showed that all oncogene-
ransfected clones of MCA-102 cells expressed higher
evels of class I MHC antigen than did nontransfected,
arental MCA-102 cells. More important for the purpose
f the above considerations, there was no correlation
etween class I antigen expression and either tumorige-
icity or NK susceptibility of the clones. Levels of Kb and
Db surface expression on all MCA-102 lines were also
easured by flow cytometry and directly correlated with
otal class I antigen levels. Therefore, levels of surface
lass I MHC antigen expression did not explain eitherhe NK phenotypes or the relative tumorigenicities of
hese oncogene-expressing cells.DISCUSSION
Viral oncogene-induced cellular immortalization is a
rerequisite for establishment of stable, neoplastic cell
lones, but this immortalization step is only part of the
xplanation for tumorigenicity. Comparison studies of
ifferent Ad serotypes and other papovaviruses have
hown that another important factor contributing to the
ifferences in the tumorigenicities of cells immortalized
y different viral oncogenes is the variable outcomes of
nteractions between oncogene-immortalized cells and
omponents of the host cellular immune response
Lewis and Cook, 1984, 1985). For example, group A and
adenoviruses are equally competent to transform
ammalian cells, but only group A Ad are oncogenic in
mmunocompetent rodents (Gallimore and Paraskeva,
980). Studies using Ad5 (nontumorigenic)–Ad12 (highly
umorigenic) chimeric viruses showed that the differ-
nces in the oncogenicities of these viruses are regu-
ated primarily by the functions of their E1A oncoproteins
Bernards et al., 1982; Jelinek et al., 1994; Telling and
illiams, 1994). These E1A differences also determine
hether Ad2/5- or Ad12-transformed cells elicit protec-
ive NK and T cell responses. Expression of Ad2/5, but
ot Ad12, E1A gene products sensitizes cells to lysis by
K cells (Cook and Lewis, 1984; Cook et al., 1986).
imilarly, Ad2/5-, but not Ad-12-, transformed cells elicit
obust CTL responses (Bellgrau et al., 1988; Pereira et al.,
1995). We speculate that a weak NK response to Ad12-
transformed cells may contribute to the subsequent fail-
ure to generate a strong Ad12-E1A-CTL response in vivo
(see below). Alternative explanations for a blunted CTL
response include the capacity of Ad12-E1A gene prod-
ucts to transrepress the expression of class I MHC
antigens and the TAP1 and TAP2 transporter genes (Ber-
nards et al., 1983; Schrier et al., 1983), an activity not
shared by Ad5-E1A gene products.
These observations suggest that, in addition to E1A-
induced cellular immortalization, E1A-induced cellular
traits that modulate the cellular immune response to
oncogene-expressing cells are an important determinant
of tumor progression or rejection. These studies may be
relevant for discerning the reasons for the dissimilar
oncogenicities of HPV and Ad in humans. In a manner
analogous to that of differences between highly onco-
genic Ad12 and nononcogenic Ad2/5-E1A genes, the
dissimilarities in oncogene function between HPV16-E7
and Ad5-E1A may influence the tumorigenicities of Ad-
and HPV-transformed cells in humans.
The studies presented here are consistent with this
hypothesis and suggest that one reason for the tumori-
genicity of E7 oncogene-expressing tumor cells is the
failure of these cells to initiate an effective antineoplastic
cellular immune response. For example, E1A expression
caused a marked reduction of the tumorigenicity of MCA-
102 cells in immunocompetent mice and a significant
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53DISSIMILAR IMMUNOGENICITIES OF E7- AND E1A-EXPRESSING CELLSreduction of MCA-102 tumorigenicity in T-cell-deficient,
NK-competent nude mice. The observation that E1A had
no effect on tumor development in CD3-e-transgenic
mice that lacked both NK cell and T cell defenses indi-
cates that this E1A-induced reduction in tumorigenicity
was caused by the combined effects of T cell and NK cell
defenses (Figs. 2 and 3 and Table 1). In contrast, E7
expression failed to induce any detectable tumor rejec-
tion response in NK- and T-cell-competent mice.
The lack of a protective T-cell-dependent response
against E7-expressing MCA-102 cells (Fig. 2) cannot be
explained by the lack of antigenicity in the E7 protein
itself in the H-2b background of the C57/BL6 mice used in
these experiments. There are several reports showing
that E7 is highly antigenic in these mice. For example, E7
peptide immunization of C57/BL6 mice induces E7-spe-
cific CTL activity (Feltkamp et al., 1993; Sadovnikova et
l., 1993). Furthermore, such CTL-inducing vaccination
trategies protect mice from tumor development by E7-
xpressing tumor cell lines (Feltkamp et al., 1995; Os-
evoort et al., 1995). This same pattern of viral oncogene-
nduced protection following preimmunization but ab-
ence of protection during primary tumor development
as been reported for several other oncogenic DNA
umor viruses, including SV40 expressed in hamster
ells and Ad12 expressed in hamster and mouse cells
Levine et al., 1984; Lewis and Cook, 1984, 1985). It is
lear, therefore, that the antigenicity of an oncoprotein
oes not guarantee its ability to induce tumor cell rejec-
ion during primary tumor formation. In fact, this is usu-
lly not the case.
This failure of E7 expression to induce primary tumor
ejection is common to both the human host faced with
PV-transformed cervical carcinoma cells and the C57/
L6 mouse challenged with E7-expressing MCA-102
ells. One possible explanation for this phenomenon that
ould be consistent with the data presented in this
eport and with our previous studies of HPV-transformed
uman cells is that there is a requirement for an “initiat-
ng interaction” between oncogene-expressing tumor
ells and NK cells that is required for effective generation
f an oncoprotein-specific CTL response. There is pre-
edent for such an accessory role for NK cells in the
eneration of a CTL response (Kos and Engleman, 1996).
or example, it has been reported that depletion of NK
ells reduces generation of syngeneic tumor-specific,
irus-specific, and allospecific CTL (Kos and Engleman,
996; Kurosawa et al., 1995; Suzuki et al., 1985). Our data
nd those in previous reports also show that certain viral
ncogenes fail to sensitize the cells they immortalize to
K killing and that these NK-insensitive oncogene-ex-
ressing cells do not induce protective, oncoprotein-
pecific anti-tumor responses. There are several exam-
les of this correlation between the ability of a DNA viral
ncogene to induce cellular sensitization to NK killing
nd the tumor-inducing capacity of the oncogene-ex-ressing cell in the immunocompetent animal. This cor-
elation has been reported for hamster and mouse cells
xpressing Ad2/5-E1A (NK susceptible and nontumori-
enic), hamster and mouse cells expressing Ad12-E1A
NK resistant and tumorigenic), SV40 T antigen-express-
ng hamster cells (NK resistant and tumorigenic), SV40 T
ntigen-expressing mouse and rat cells (NK sensitive
nd nontumorigenic), polyoma T antigen-expressing
amster cells (NK resistant and tumorigenic), and human
ells expressing HPV16- or HPV18-E7 and -E6 (NK resis-
ant and tumorigenic) (Cook et al., 1980, 1982; Cook and
ewis, 1984; Fresa et al., 1987; Raska and Gallimore,
982; Routes and Ryan, 1995; Sawada et al., 1985). The
ata reported here extend this correlation to E7-express-
ng MCA-102 cells (NK resistant and tumorigenic) and
uggest that this same pattern of resistance for HPV16-
r HPV-E7-expressing human tumor cells may be rele-
ant in vivo. Furthermore, neither the NK sensitivity nor
umorigenicities of the different MCA-102 lines were re-
ated to class I MHC antigen expression. These data are
n agreement with other studies relating NK sensitivity
nd either tumorigenicity or class I expression on Ad-
ransformed or E1A-transfected rodent and human cell
ines (Haddada et al., 1986, 1988; Routes and Cook,
1995). Studies are ongoing to determine if the expression
of nonclassical class I antigens influences the NK sen-
sitivities of E1A- and E7-expressing murine and human
tumor cell lines.
The inability of E7-expressing MCA-102 cells to induce
protective T-cell-dependent responses in immunocom-
petent mice is also consistent with observations of HPV-
transformed cells in humans and other types of E7-
transfected tumor cells in mice. For example, E7- or
E6-specific CTL are inefficiently generated in women
with HPV-induced cervical cancer (Borysiewicz et al.,
1996; Evans et al., 1996; Ressing et al., 1996). Similarly,
injection of HPV16-E7-transfected tumor cells that are
not co-transfected with the co-stimulatory molecule B7.1
fail to induce E7-specific CTL in mice (Chen et al., 1992).
Thus, our findings are consistent with the hypothesis that
the E7 and E6 oncoproteins are ignored by the immune
system despite their antigenicity, a state referred to as
immunological ignorance (Melero et al., 1997).
HPV infect only human keratinocytes with complete
viral replication linked to the differentiation of the in-
fected cell. HPV gene products that help circumvent the
host immune response to HPV infection may exist. In
addition, the urogenital location of HPV-induced malig-
nancies as well as differences in the replicative cycle
and the unique cell tropism of HPV may contribute to the
dissimilar oncogenicities of HPV and Ad. However, we
believe that these are not the only factors leading to the
dissimilar oncogenicities of Ad and HPV. Ad are ubiqui-
tous human pathogens that cause persistant infections
with asymptomatic fecal excretion for months to years
following the initial infection (Fox et al., 1969). Ad infect
H
c
(
E
G
n
A
p
H
v
s
n
P
d
o
C
w
m
m
t
M
M
N
u
t
(
1
a
a
w
W
M
l
S
c
t
a
o
p
H
m
n
s
e
w
f
h
p
s
K
E
w
0
1
f
l
r
54 ROUTES ET AL.epithelial (including keratinocytes), fibroblastic, and lym-
phoidal cells. Ad can cause both asymptomatic and
symptomatic urogenital tract infections (Mufson et al.,
1973). Like HPV-E7/E6, Ad-E1A/E1B are competent to
completely transform both epithelial and fibroblastic
cells in vitro. Furthermore, Ad-transformed human cells
are tumorigenic in immunodeficient animals (Chang et
al., 1990). Therefore, the fact that Ad can infect and
potentially transform cells at virtually any anatomic loca-
tion, including locations in which HPV replicate, pre-
cludes the possibility that the cell tropism and anatomic
site of HPV-induced malignancy is the only explanation
for the dissimilar oncogenicities of Ad and HPV. Finally,
although there may be HPV proteins produced that cir-
cumvent cellular immunity to HPV infection, these pro-
teins likely would not affect the cellular immune re-
sponse following viral transformation. HPV-transformed
cells are virion free and no further viral replication is
possible (Galloway and McDougall, 1989). Only two viral
proteins are consistently expressed in HPV-transformed
cells, the E7 and E6 oncoproteins.
In summary, the data reported here show that the
dissimilar immunogenicities of the E1A and E7 oncopro-
teins can influence primary tumor development. We pos-
tulate that differences similar to those observed in this
mouse model might also exist in the cellular immune
responses to human cells expressing Ad5-E1A or
HPV16-E7. This hypothesis predicts that, following Ad5
transformation of human cells, E1A expression would
elicit a robust NK cell and T cell response that results in
destruction of these cells in vivo. In contrast, following
HPV16 transformation, E7 expression would fail to elicit
such an immune response and would, therefore, persist
to allow cellular transformation, subsequent cellular mu-
tations, and tumor progression. These observations pro-
vide a basis for future studies contrasting E7 and E1A to
test cellular mechanisms that explain the failure of E7 to
sensitize tumor cells to NK killing and to induce T-cell-
dependent tumor rejection by immunocompetent ani-
mals.
MATERIALS AND METHODS
Cell lines
The methylcholanthrene-induced sarcoma cell line
MCA-102 was provided by Dr. Nicholas Restifo (National
Institutes of Health, Bethesda, MD) (Mule et al., 1987).
4-E7 cells are HT1080-derived, human fibrosarcoma
ells expressing high levels of the HPV16-E7 oncoprotein
Routes and Ryan, 1995). MCA-102 cells expressing Ad5-
1A or HPV16-E7 were derived from clones selected in
418 following transfection with pLSXN16E7 or pE1A-
eo, which code for G418 resistance and HPV16-E7 or
d5-E1A, respectively. G418-resistant colonies were ex-
anded and screened for the expression of Ad5-E1A or
PV16-E7 by Western analysis. pLSXN16E7 was pro-
s
(ided by Denise Galloway (Fred Hutchinson Cancer Re-
earch Center, Seattle, WA) (Halbert et al., 1991). pE1A-
eo was provided by Elizabeth Moran (Temple University,
hiladelphia, PA) (Ruley et al., 1985). Two independently
erived clones of MCA-102 cells expressing high levels
f either Ad5-E1A (MCA-102-E1A-CL1, MCA-102-E1A-
L2) or HPV16-E7 (MCA-102-E7-CL1, MCA-102-E7-CL2)
ere used for all studies. The MCA-102 cell lines were
aintained in DMEM supplemented with antibiotics, 15
M glucose, and 5% FCS. Cell lines were periodically
ested for contamination with mycoplasma using the
ycotec assay (Bethesda Research Labs, Bethesda,
D) and were negative.
K cell cytolysis assays
NK cytolysis assays were performed as described
sing spleen cells from athymic nude C57/B6 mice as
he source of NK cells and target cells labeled with [51Cr]
100 mCi/ml for 1 h; 1 Ci 5 37 gBq) (Routes and Cook,
995). The results shown represent the means 6 SEM of
t least four separate experiments. The mean percent-
ge spontaneous release from all types of target cells
as less than 20%.
estern analysis
For quantitation of E1A proteins, 60-mm plates of
CA-102-E1A-CL1 or MCA-102-E1A-CL2 cells were
ysed in RIPA buffer (1% NP-40, 0.5% deoxycholate, 0.1%
DS, 50 mM Tris, pH 7.4, 150 mM NaCl), and protein
oncentrations of RIPA supernatants were determined by
he BCA protein assay (Pierce, Rockford, IL). An equal
mount of protein from each cell lysate was separated
n 10% SDS–PAGE polyacrylamide gels and electro-
horetically transferred to PVDF membrane (Bio-Rad,
ercules, CA). The membrane was blocked in 5% nonfat
ilk solution and incubated with the anti-E1A monoclo-
al antibody, M73, supplied by E. Harlow (Massachu-
etts General Hospital, Charleston, MA) for 1 h (Harlow
t al., 1985). Following several washes with PBST (PBS
ith 0.05% Triton X-100), the membranes were incubated
or 1 h with rabbit anti-mouse antibody (Cappel, Durn-
am, NC) and washed extensively with PBST. The E1A
rotein was then visualized per the manufacturer’s in-
tructions using the Renaissance Chemiluminescence
it (DuPont–NEN, Boston, MA).
For quantitation of E7 proteins, 100-mm plates of H4-
7, SiHa, or MCA-102-E7-CL1 and CL2 cells were lysed
ith the E7 lysis buffer (20 mM Tris, ph-7.5, 150 mM NaCl,
.5% SDS, 0.5% NP-40, 0.5% deoxycholate, 1 mM EDTA,
% aprotinin, and 1 mM PMSF). Protein concentrations
rom each lysate were determined and equal amounts of
ysate were immunoprecipitated using Protein A Sepha-
ose CL-4B beads (Amersham Pharmacia Biotech, Upp-
ula, Sweden) and the E7 monoclonal antibody ED17
Santa Cruz Biotechnology, Santa Cruz, CA). Immunopre-
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transferred to PVDF membrane. With the exception of the
use of the monoclonal E7 antibody, the remainder of the
Western analysis was identical to the procedure used for
the detection of the E1A proteins.
Tumor induction studies
CD3-e-transgenic mice and congenitally athymic nude
nd normal C57/BL6 mice were obtained from Jackson
aboratories. CD3-e-transgenic mice do not express ei-
ther T cells or NK cells (Wang et al., 1994). Quantitative
tumor induction studies were performed as previously
described (Walker et al., 1991). Briefly, mice (three ani-
mals per cell dose for normal and athymic nude mice,
two animals per dilution for CD3-e-transgenic mice) were
injected subcutaneously with serial log concentrations of
cells and observed weekly for tumor development for 12
weeks. Animals were sacrificed when tumors reached a
mean diameter of 20 mm or at the end of the 12-week
observation period. Tumor cells from animals injected
with either MCA-102-E1A or MCA-102-E7 cells were
tested for E1A or E7 expression. TPD50 (log10 of the
number of tumor cells required to produce tumors in 50%
of the mice) were calculated by the method of Karber
(1931).
Measurement of class I MHC antigen levels
M1/42.3.98, a monoclonal antibody that is panreactive
to all murine class I antigens, was obtained from the
American Tissue Culture Collection. The MCA-102 lines
were stained with M1/42.3.98, and 5000 cells were ana-
lyzed on an Epics C flow cytometer as described (Routes
and Cook, 1990). The levels of surface class I antigens
on the E1A- or E7-transfected cell lines were normalized
to parental MCA-102 cells using linearized values of log
mean fluorescence. The results in the text represent the
means 6 SEM of at least three experiments. Levels of Kb
and Db surface expression on all MCA-102 lines were
lso measured by flow cytometry and directly correlated
ith total class I antigen levels.
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